This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Applied Therapeutics Crescita futura

Criteri Future verificati 2/6

Si prevede che gli utili di Applied Therapeutics diminuiranno del 33.9% all'anno, mentre si prevede che il fatturato annuo crescerà del 55.3% all'anno. Si prevede che l'EPS diminuirà del 0.05% all'anno.

Informazioni chiave

-33.9%

Tasso di crescita degli utili

-0.049%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	23.0%
Tasso di crescita dei ricavi	55.3%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	12 Dec 2025

Aggiornamenti recenti sulla crescita futura

Recent updates

Here's Why Applied Therapeutics (NASDAQ:APLT) Must Use Its Cash Wisely

Jul 15

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Nov 15

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Sep 18

Applied Therapeutics: Pushing Towards FDA Approval

Sep 04

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Aug 01

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

May 28

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:APLT - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2028	65	N/A	N/A	N/A	1
12/31/2027	4	-83	N/A	N/A	2
12/31/2026	1	-69	N/A	N/A	4
12/31/2025	1	-76	N/A	N/A	4
9/30/2025	1	-18	-87	-87	N/A
6/30/2025	0	-68	-92	-92	N/A
3/31/2025	0	-44	-94	-94	N/A
12/31/2024	0	-106	-84	-84	N/A
9/30/2024	0	-187	-82	-82	N/A
6/30/2024	0	-161	-73	-73	N/A
3/31/2024	0	-194	-67	-67	N/A
12/31/2023	10	-120	-55	-55	N/A
9/30/2023	11	-97	-54	-54	N/A
6/30/2023	11	-73	-59	-59	N/A
3/31/2023	11	-70	-61	-61	N/A
12/31/2022	N/A	-83	-78	-78	N/A
9/30/2022	N/A	-95	-89	-89	N/A
6/30/2022	N/A	-105	-85	-85	N/A
3/31/2022	N/A	-105	-93	-93	N/A
12/31/2021	N/A	-106	-91	-91	N/A
9/30/2021	N/A	-102	-87	-87	N/A
6/30/2021	N/A	-104	-92	-92	N/A
3/31/2021	N/A	-106	-82	-82	N/A
12/31/2020	N/A	-94	-78	-78	N/A
9/30/2020	N/A	-88	-68	-68	N/A
6/30/2020	N/A	-69	-55	-55	N/A
3/31/2020	N/A	-49	-48	-48	N/A
12/31/2019	N/A	-46	-36	-36	N/A
9/30/2019	N/A	-35	-30	-30	N/A
6/30/2019	N/A	-28	N/A	-24	N/A
3/31/2019	N/A	-23	N/A	-17	N/A
12/31/2018	N/A	-17	N/A	-11	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che APLT rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che APLT rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che APLT rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di APLT ( 55.3% all'anno) crescerà più rapidamente del mercato US ( 10.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di APLT ( 55.3% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di APLT è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/02/02 05:00
Prezzo dell'azione a fine giornata	2026/02/02 00:00
Utili	2025/09/30
Utili annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub, abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Applied Therapeutics, Inc. è coperta da 7 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Carter Gould	Barclays
Paul Choi	Goldman Sachs
Luke Davis	RBC Capital Markets

This company has been acquired

Applied Therapeutics Crescita futura

Criteri Future verificati 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates decrease by 73%, EPS upgraded

Price target decreased by 50% to US$3.17

Consensus revenue estimates decrease by 38%

Consensus revenue estimates decrease by 26%

Forecast to breakeven in 2026

Consensus EPS estimates fall by 36%

Recent updates

Cycle Group Holdings Limited completed the acquisition of Applied Therapeutics, Inc. (NasdaqCM:APLT) for approximately $14.3 million.

Wolf Popper LLP Announces A Proposed Class Action Settlement Regarding Purchasers of Applied Therapeutics, Inc. Common Stock

Cycle Group Holdings Limited entered into a definitive agreement to acquire Applied Therapeutics, Inc. (NasdaqCM:APLT) for $13.4 million.

Applied Therapeutics Announces Reduction of Workforce by Approximately 46%

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Applied Therapeutics, Inc. Announces Resignation of John Johnson as Executive Chairman and as Director in November 2025

Applied Therapeutics, Inc. Provides Update Following Meeting with FDA

New major risk - Share price stability

Applied Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Consensus revenue estimates decrease by 73%, EPS upgraded

Price target decreased by 50% to US$3.17

First half 2025 earnings released: US$0.30 loss per share (vs US$0.60 loss in 1H 2024)

Here's Why Applied Therapeutics (NASDAQ:APLT) Must Use Its Cash Wisely

Applied Therapeutics Announces Leadership Appointments

Applied Therapeutics, Inc. Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

Applied Therapeutics, Inc., Annual General Meeting, Jun 09, 2025

Applied Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Applied Therapeutics, Inc. announced delayed annual 10-K filing

Applied Therapeutics, Inc. Appoints Todd F. Baumgartner as Chief Regulatory Officer

Applied Therapeutics Receives Written Notification from Nasdaq Regarding Bid Price Requirement

Applied Therapeutics, Inc. Appoints Reena Thomas Colacot as Head of Quality

Applied Therapeutics, Inc Announces Chief Executive Officer Changes

Robbins Geller Rudman & Dowd LLP Announces That Applied Therapeutics, Inc. Investors with Substantial Losses Has Opportunity to Lead the Applied Therapeutics Class Action Lawsuit

Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

Applied Therapeutics: Pushing Towards FDA Approval

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

Consensus revenue estimates decrease by 38%

Consensus revenue estimates decrease by 26%

Forecast to breakeven in 2026

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

Chair of the Board of Directors recently sold US$1.7m worth of stock

New major risk - Revenue and earnings growth

Applied Therapeutics, Inc. announced that it expects to receive $99.997998 million in funding from a group of investors

Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Applied Therapeutics, Inc. Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

Independent Director recently bought US$65k worth of stock

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

Consensus EPS estimates fall by 36%

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

New major risk - Shareholder dilution

Consensus EPS estimates fall by 13%

Consensus revenue estimates fall by 27%

New major risk - Financial position

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Consensus revenue estimates decrease by 21%

Consensus revenue estimates increase by 89%

Consensus revenue estimates increase by 1,731%

Applied Therapeutics Announces Positive Sorbitol Reduction Data from the Ongoing Phase 3 Inspire Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Price target increased by 27% to US$15.00

Insufficient new directors

Price target increased to US$16.50

Applied Therapeutics, Inc.(NasdaqGM:APLT) dropped from Russell 2000 Growth Index

Applied Therapeutics Receives Orphan Medicinal Product Designation from the Ema for AT-007 for Treatment of Galactosemia

Insufficient new directors

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

Price target decreased to US$12.10

Applied Therapeutics, Inc., Annual General Meeting, Jun 02, 2022